• 1
    Wiseman GA, White CA, Stabin M, Dunn WL, Erwin W, Dahlbom M, et al. Phase I/II 90Y-Zevalin (yttrium-90 ibritumomab tiuxetan, IDEC-Y2B8) radioimmunotherapy dosimetry results in relapsed or refractory non-Hodgkin's lymphoma. Eur J Nucl Med 2000; 27: 76677.
  • 2
    Wahl RL, Kroll S, Zasadny KR. Patient-specific whole-body dosimetry: principles and a simplified method for clinical implementation. J Nucl Med 1998; 39: 14s20s.
  • 3
    Siegel JA, Lee RE, Pawlyk DA, Horowitz JA, Sharkey RM, Goldenberg DM. Sacral scintigraphy for bone marrow dosimetry in radioimmunotherapy. Nucl Med Biol 1989; 16: 5539.
  • 4
    Sgouros G. Bone marrow dosimetry for radioimmunotherapy: theoretical considerations. J Nucl Med 1993; 34: 68994.
  • 5
    Siegel JA, Wessels BW, Watson EE, Stabin MG, Vriesendorp HM, Bradley EW, et al. Bone marrow dosimetry and toxicity for radioimmunotherapy. Antibody Immunoconj Radiopharm 1990; 3: 21333.
  • 6
    Sgouros G, Stabin M, Erdi Y, Akabani G, Kwok C, Brill AB, et al. Red marrow dosimetry for radiolabeled antibodies that bind to marrow, bone, or blood components. Med Phys 2000; 27: 215064.
  • 7
    Hellstrom I, Garrigues HJ, Garrigues U, Hellstrom KE. Highly tumor-reactive, internalizing, mouse monoclonal antibodies to Ley-related cell surface antigens. Cancer Res 1990; 50: 218390.
  • 8
    Chen JQ, Strand S-E, Brechbiel MW, Gansow OA, Sjögren H-O. Combination of biotinylation and indium-111 labelling with chelate SCN-Bz-CHX-A-DTPA for chimeric BR96: biodistribution and pharmacokinetic studies on colon carcinoma isografted rats. Tumor Targeting 1996; 2: 6675.
  • 9
    Chen JQ, Strand S-E, Isaksson M, Ljunggren K, Sjögreen K, Garkavij M, et al. Biodistribution and pharmacokinetics of 125-I/131-I pair-labeled, biotinylated chimeric BR96 in colon carcinoma isografted rats. Tumor Targeting 1996; 2: 20414.
  • 10
    Chen JQ, Strand S-E, Tennvall J, Hindorf C, Sjögren H-O. Biodistribution and pharmacokinetics of biotinylated 188Re-chiBR96 in colon carcinoma isografted rats. Tumor Targeting 1998; 3: 8795.
  • 11
    Lindén O, Tennvall J, Cavallin-Ståhl E, Darte L, Garkavij M, Lindner K-J, et al. Radioimmunotherapy using 131I-labeled anti-CD22 monoclonal antibody (LL2) in patients with previously treated B-cell lymphomas. Clin Cancer Res 1999; 5: 3287s91s.
  • 12
    Weadcock KS, Sharkey RM, Varga DC, Goldenberg DM. Evaluation of a remote radioiodination system for radioimmunotherapy. J Nucl Med 1990; 31: 50811.
  • 13
    Stabin MG. MIRDOSE: personal computer software for internal dose assessment in nuclear medicine. J Nucl Med 1996; 37: 53846.
  • 14
    Jönsson B-A, Strand S-E, Larsson BS. A quantitative autoradiographic study of the heterogeneous activity distribution of different indium-111–labeled radiopharmaceuticals in rat tissues. J Nucl Med 1992; 33: 182533.
  • 15
    Johnson TK, Gonzalez R, Kasliwal RK, Lear JL, Feyerabend AJ, Dienhart DG, et al. Distribution of a breast-directed I-131–radiolabeled monoclonal antibody in blood and bone marrow: implications for radiation immunotherapy. Radiology 1992; 182: 10714.
  • 16
    van Gog FB, Brakenhoff RH, Snow GB, van Dongen GAMS. Rapid elimination of mouse/human chimeric monoclonal antibodies in nude mice. Cancer Immunol Immunother 1997; 44: 10311.
  • 17
    Weinstein JN, Steller MA, Keenan AM, Covell DG, Key ME, Sieber SM, et al. Monoclonal antibodies in the lymphatics: selective delivery to lymph node metastases of a solid tumor. Science 1983; 222: 4236.
  • 18
    Rubin P, Finkelstein JN, Siemann DW, Shapiro DL, Van Houtte P, Penney DP. Predictive biochemical assays for late radiation effects. Int J Radiat Oncol Biol Phys 1986; 12: 46976.